From: Therapeutic nanoplatforms and delivery strategies for neurological disorders
Targeting disease | Loading molecule | Purpose | Material | Targeting strategy | Refs. | |
---|---|---|---|---|---|---|
LBNP | GBM | Doxorubicin, vincristine | Anticancer | Liposome | T7 peptide | [11] |
Doxorubicin | Anticancer | Liposome | Chlorotoxin | [8] | ||
Doxorubicin | Anticancer | Liposome | IL-13 | [9] | ||
Coumarin-6 | In vivo imaging | Liposome | RGD, Transferrin | [10] | ||
AD | si-BACE | AD treatment | Exosome | Lamp-2b | [50] | |
PD | Dopamine HCl | PD treatment | Liposome | – | [30] | |
L-DOPA | PD treatment | Liposome | Chlorotoxin | [31] | ||
PNP | GBM | Docetaxel | Anticancer | PEG‐PCL | AS14111 aptamer | [12] |
Paclitaxel | Anticancer | PEG‐PLGA | AS14111 aptamer | [13] | ||
Paclitaxel | Anticancer | PLGA | Transferrin | [14] | ||
Paclitaxel | Anticancer | PEG-PLGA | Pep-1 | [15] | ||
Paclitaxel | Anticancer | PEG-PCL | Angiopep | [62] | ||
AD | Curcumin | AD treatment | PBCA | ApoE3 | [63] | |
– | PET | PBCA | 125I-clioquinol | [64] | ||
PD | α-synuclein | PD treatment | PBCA | ApoE | [65] | |
L-DOPA | PD treatment | PLGA | – | [59] | ||
Nicotine | PD treatment | PLGA | – | [60] | ||
Ropinirole-HCl | PD treatment | Chitosan | – | [58] | ||
IO-NP | GBM | – | MRI | PEG-ION | Chlorotoxin | [84] |
– | MRI | Dex-SIPON | Chitosan | [86] | ||
– | MRI/TEM | PEG-ION | Anti-EGFRviii | [85] | ||
AD | – | MRI | SPION | Anti-AβPP | [88] | |
– | MRI | Dextran-ION | Anti-ferritin | [89] | ||
PD | Rhodamine-B | MRI | MION | – | [156] | |
Au-NP | GBM | Phthalocyanine 4 | PDT | PEG-Au-NP | Transferrin peptide | [16] |
– | PTT | PEG-Au-NP | – | [105] | ||
– | PTT | PEG-Au-NP | RVG29 peptide | [17] | ||
AD | Polyoxometalate | AD treatment | Au-NP | – | [138] | |
PD | Si-α-synuclein | PD treatment | Au-NP | Chitosan | [157] |